ONWARD has begun enrolment in the LIFT Home study, which is designed to examine the safety and performance of its ARCEX Therapy for spinal cord injury (SCI) when used in a home setting.
ONWARD’s ARCEX Therapy is externally delivered programmed stimulation of the spinal cord which is designed to restore strength and function in people with SCI and other movement related challenges.
The study will enrol up to 20 participants at five research centres in the United State. Subjects will be followed for four weeks to assess whether continued access to ONWARD’s ARCEX Therapy is safe and can be used to enhance long-term benefit.
The first participants have been enrolled at Craig Hospital (Denver, USA) under the supervision of study principal investigator, Candy Tefertiller, and at the University of Washington (Seattle, USA) by Chet Moritz.
“The LIFT Home study is an important next step in understanding the potential benefits people with spinal cord injury may derive from continued access to ARCEX Therapy outside the clinic,” said Tefertiller.
Dave Marver, CEO of ONWARD, said: “We are pleased to collaborate with an outstanding group of researchers to investigate new potential benefits and care settings for our ARCEX Therapy. This is another step in our journey to help people with spinal cord injury live better, more independent lives.”